Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$49.19M+14.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yoshiyuki Aikawa
- Sector
- Industrials
- Industry
- Consulting Services
- Employees
- 863
- Beta
- 0.63
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.95
Financials
Revenue
$49.19M+14.6%Net Income
$10.69M+78.1%EBITDA
$18.25M+21.1%Free Cash Flow
$22.04M+649.8%EPS (diluted)
$0.10+145.7%Shares Outstanding (diluted)
102.58M+580.8%Operating Expenses
$17.02MCash & Debt
$184.62MReturn of Capital
$0.00Revenue by Segment (annual)
$173.61MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $173.61M | $50.99M | $0.50 |
| 2024 | $205.42M | $46.61M | $0.48 |
| 2023 | $193.54M | $39.37M | $0.42 |
| 2022 | $174.16M | $6.32M | $0.06 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SBC's reported EPS growth of 99.8% a year over 3 years. Historical EPS growth of 100% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $1.84
- Implied price
- $16.54
- Return from $5.34
- 25.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.22 — today's price is already 35.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| 20.0% | 2.9% | 10.1% | 15.7% | 20.5% | 24.6% |
| 25.0% | 7.2% | 14.6% | 20.6% | 25.5% | 29.8% |
| 30.0% | 11.5% | 19.2% | 25.4% | 30.5% | 34.9% |
| 35.0% | 15.8% | 23.8% | 30.2% | 35.5% | 40.1% |
| 40.0% | 20.0% | 28.4% | 35.0% | 40.5% | 45.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·11d ago·Neutral
SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026 IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in October 2026.
View source ↗ - Newsbusinesswire.com·34d ago·Neutral
SBC Medical to Participate in Several Upcoming Investor Conferences in September 2026 IRVINE, Calif.--(BUSINESS WIRE)-- #Healthcare--SBC Medical will be conducting a Non-Deal Roadshow (NDR) and participating in several investor conferences throughout September 2026.
View source ↗ - Newsmarketbeat.com·37d ago·Neutral
SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2 SBC Medical Group NASDAQ: SBC said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management services revenue and increased service fees.
View source ↗ - Newsaccessnewswire.com·39d ago·Negative
Emerging Growth Research Issues Updated Press Release Announcing Company-Sponsored Research on SBC Medical Group Holdings Incorporated NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research quarterly update on SBC Medical Group Holdings Incorporated (NASDAQ:SBC), which, together with its subsidiaries, provides management services to cosmetic treatment centers via a f…
View source ↗ - Newsmarketbeat.com·47d ago·Neutral
SBC Medical Group Q2 Growth Re-Accelerates as EBITDA Surges 32% SBC Medical Group NASDAQ: SBC said its growth re-accelerated in the second quarter of 2026 as the company completed structural reforms undertaken in 2025, expanded its clinic network and increased management-services revenue.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
SBC Medical Group Holdings Incorporated (SBC) Q2 2026 Earnings Call Transcript SBC Medical Group Holdings Incorporated (SBC) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
SBC Medical Group Q2 Earnings Call Highlights SBC Medical Group NASDAQ: SBC said its second-quarter 2026 results reflected a reacceleration in growth following structural reforms undertaken in 2025, with adjusted EBITDA rising faster than revenue despite the effect of a weaker yen on reported results.
View source ↗ - Newsbusinesswire.com·54d ago·Neutral
SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results IRVINE, Calif.--(BUSINESS WIRE)-- #Healthcare--Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Up 335%, Adjusted EBITDA1 Up 32% Year-over-Year.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $0.11 per share
Typical surprise -7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.10 vs $0.12miss
- Thu, May 14$0.11 vs $0.10beat
- Fri, Mar 27$0.14 vs $0.13beat
- Fri, Nov 14$0.12 vs $0.13miss
- Wed, Aug 13$0.02 vs $0.14miss
- Thu, May 15$0.21 vs $0.11beat
Estimates and results for SBC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SBC officers and directors.
- Bought
- —
- Sold
- $31.7m
0 trades
17 trades
- Aikawa Yoshiyukisold
- Aikawa Yoshiyukisold
- Aikawa Yoshiyukisold
- Zuu Co. Ltd.sold
- Dorman David Wsold
- Dorman David Wsold
- Dorman David Wsold
- Dorman David Wsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SBC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.